ArticleMethods in molecular biology (Clifton, N.J.)2026
The Use of Bioengineered Induced Pluripotent Stem Cell-Derived Human Megakaryocytes to Diagnose and Characterize Platelet Allo-, Auto-, and Iso-Immune Disorders.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-platelet allo-, auto-, and iso-antibodies, which target platelet surface glycoproteins, play a crucial role in immune-mediated platelet destruction across various clinical scenarios. Whole cell platelet assays-while effective in maintaining the conformation of the offending antigen-are limited in characterizing anti-platelet antibodies due to their lack of specificity. Here, we describe a novel strategy for generating bioengineered HLA class I-negative, "antigen-specific" megakaryocytes (MKs) from induced pluripotent stem cells (iPSCs). These engineered cells can be cryopreserved for later distribution and analysis. Combining bioengineered megakaryocytes with flow cytometry allows for rapid detection and characterization of platelet-specific antibodies present in patient plasma. The enhanced sensitivity and remarkable specificity of this approach hold great promise for diagnosing a variety of immune platelet disorders.
Indexed as
Identifiers
42681436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.